Market Research Report
Treatment-resistant depression (TRD) - Market Insights, Epidemiology, and Market Forecast - 2030
|Treatment-resistant depression (TRD) - Market Insights, Epidemiology, and Market Forecast - 2030|
DelveInsight Business Research LLP
Content info: 200 Pages
Delivery time: 2-10 business days
DelveInsight's 'Treatment-resistant depression (TRD) - Market Insights, Epidemiology, and Market Forecast - 2030' report delivers an in-depth understanding of the Treatment-resistant depression (TRD), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Treatment-resistant depression (TRD) market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted TRD symptoms market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Treatment-resistant depression (TRD) symptoms treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2017-2030
Treatment-resistant depression (TRD) Overview
Treatment-resistant depression (TRD) is a major depressive disorder (MDD) that does not respond to traditional and first-line therapeutic options. MDD is a mood disorder that causes a persistent feeling of sadness and loss of interest, which can interfere with day-to-day life. Depression lasting at least 2 weeks along with meeting about five or more of the DSM-V criteria (of MDD) is considered as MDD. Further, those with at least one episode in the prior 12 months are classified as 12-month MDD. The World Health Organization (WHO) designated major depressive disorder (MDD) as the fourth leading cause in the world. Despite the widespread availability of effective treatments for depression, many patients do not receive adequate relief from symptoms.
The exact biological mechanisms leading to depression are unknown; however, theories include the monoamine hypothesis, the genetic hypothesis, and the chronic stress hypothesis. The monoamine hypothesis suggests that depressive symptoms are mainly related to a deficit in the availability of norepinephrine, dopamine, or serotonin neurotransmitters, thereby explaining the mechanism of action of most antidepressant medications
Symptoms of depression overlap those of other psychiatric disorders. Anxiety, PTSD, and panic disorder can coexist with depression; therefore, it has chances to be misdiagnosed. Along with this, one of the perils of diagnosing TRD is that of "pseudo-resistance". Further, comorbidities such as anxiety disorders, personality disorders, or substance-use disorders may complicate the clinical picture and can have deleterious effects on treatment response. Clinicians need to accurately diagnose TRD by examining primary and secondary (organic) causes of depression and acknowledging paradigm failures that contribute to a misdiagnosis of TRD.
Treatment-resistant depression (TRD) Diagnosis and Treatment
It covers the details of conventional and current medical therapies and diagnosis available in the Treatment-resistant depression (TRD) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The DelveInsight Treatment-resistant depression (TRD) market report gives a thorough understanding of TRD symptoms by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides TRD symptoms of treatment algorithms and treatment guidelines for TRD symptoms in the US, Europe, and Japan.
The Treatment-resistant depression symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted Treatment-resistant depression (TRD) epidemiology segmented as the Diagnosed Prevalent cases of Treatment-resistant depression (TRD), Gender-specific cases of Treatment-resistant depression (TRD), Age-specific cases of Treatment-resistant depression (TRD), The report includes the Prevalent scenario of TRD symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
The epidemiology segment also provides the Treatment-resistant depression (TRD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The total Diagnosed Prevalent population of Treatment-resistant depression (TRD) in 7MM countries was estimated to be 4,464,781 cases in 2017.
The drug chapter segment of the Treatment-resistant depression (TRD) report encloses the detailed analysis of TRD marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Treatment-resistant depression (TRD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
The therapeutic market size of TRD in the US is mainly accounted for treatment options, such as pharmacologic treatment options and Non-pharmacological therapies. Pharmacologic treatment options include switching, combination and potentiation strategy among the commonly used antidepressants drugs such as Selective Serotonin Reuptake Inhibitor (SSRI), Dual serotonin and norepinephrine reuptake inhibitors (SNRIs), Tricyclic antidepressant, Irreversible, non-selective monoamine oxidase inhibitors (MAOIs), α2-antagonists, Agomelatine, Tianeptine that are used to treat TRD
Products detail in the report…
Treatment-resistant depression (TRD) Emerging Drugs
AXS-05 (Axsome Therapeutics)
AXS-05 is a novel, oral, an investigational medicine, a combination of bupropion and dextromethorphan. For TRD, adding BUP to DM has the effect of boosting monoamines for conventional depression treatment while targeting unconventional mechanisms (Sigma-1 and NMDA). Axsome Therapeutics is investigating this fixed-dose combination in the Phase III stage of development and planning for NDA submission by the end of 2020 based on the positive results. It has received breakthrough therapy for MDD and fast-Track designation for TRD with spectacle multiple (7) MOAs.
Products detail in the report…
The Treatment-resistant depression (TRD) market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Treatment-resistant depression (TRD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Treatment-resistant depression (TRD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Treatment-resistant depression (TRD) market in 7MM is expected to change in the study period 2017-2030.
At present, the therapeutic market size of TRD in the US is mainly accounted for by the management options consisting of pharmacologic treatment options and non-pharmacological therapies.
Pharmacologic treatment options include switching, combination, and potentiation strategy among the commonly used antidepressant drugs. Most of the available antidepressants such as Selective Serotonin Reuptake Inhibitor (SSRI), Dual serotonin and norepinephrine reuptake inhibitors (SNRIs), Tricyclic antidepressant, Irreversible, non-selective monoamine oxidase inhibitors (MAOIs), α2-antagonists, Agomelatine, Tianeptine are used to treat TRD.
Non-pharmacological therapies include electroconvulsive therapy (ECT), Repetitive transcranial magnetic stimulation (rTMS), and Vagus nerve stimulation (VNS). Along with this, two alternative forms of psychotherapy involve majorly cognitive-behavioral therapy (CBT) and interpersonal therapy (IPT).
This section includes a glimpse of the Treatment-resistant depression (TRD) market in 7MM. The market size of TRD in the seven major markets was found to be USD 1,736.4 Million in 2017.
This section provides the total Treatment-resistant depression (TRD) market size and market size by therapies in the United States.
The United States accounts for the highest market size of TRD in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
Spravato and Symbyax are the two FDA approved drugs specifically for the treatment of TRD. Other pharmacologic alternatives are also considered those having an antidepressant action such as in monotherapy: Bupropion, selective and reversible MAOIs, Quetiapine, and in combination with a first-line antidepressant: Lithium, Lamotrigine and second-generation antipsychotics.
Switching is recommended when there is no response or poor tolerance to the initial treatment, poor response to the newly introduced treatment. Selective Serotonin Reuptake Inhibitor (SSRI) is considered a first-line treatment, regardless of the clinical severity. When there is no response from SSRI, norepinephrine reuptake inhibitors (SNRIs) are considered as a choice of treatment. However, in some cases there is no response from SNRIs, the next approach is a tricyclic antidepressant.
The combination strategy (i.e. adding another antidepressant to an existing one) is only recommended in cases of partial response, after 4 to 6 weeks of adequate treatment. In the first-line treatment, the recommended strategies consist of combinations such as SSRI + α2 antagonist, SNRI + α2 antagonist, and Tricyclic antidepressant + α2-antagonist. In the second-line treatment, an association between SSRIs, SNRIs, or tricyclic antidepressant and agomelatine can be proposed.
The total Treatment-resistant depression (TRD) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Among the current practices, majorly switching can be envisaged among antidepressant drugs (SSRI, SNRIs, IMAOs, and others) in there different strategies i.e., Concurrent switch, Overlapping switch, Sequential switch. The concurrent switch is recommended, except when the patient is currently receiving a monoamine oxidase inhibitor (MAOI) medication in which a sequential approach is required during the switching process.
General prescribing figures for England have shown, SSRIs are the most common type of antidepressant used in patients with TRD estimated at 79%. Citalopram and fluoxetine accounted for 67% of all antidepressants. Whereas, monotherapy and augmented antidepressant treatment are very rare.
The total Treatment-resistant depression (TRD) market size and market size by therapies in Japan are also mentioned.
This section focusses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers Treatment-resistant depression (TRD) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.
Treatment-resistant depression (TRD) Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Treatment-resistant depression (TRD) key players involved in developing targeted therapeutics.
Major players include Janssen Pharmaceuticals, Axsome Therapeutics, Alkermes, Allergan/ Gedeon Richter, Minerva Neurosciences, Acadia Pharmaceuticals, Novartis, Celon Pharma, COMPASS Pathways, Relmada Therapeutics, Vistagen Therapeutics, OcuNexus Therapeutics, Eyevance Pharmaceuticals.
Cariprazine (Allergan/ Gedeon Richter), is expected to get launched in the US market by 2022.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Treatment-resistant depression (TRD) emerging therapies.
Reimbursement Scenario in Treatment-resistant depression (TRD)
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business & price strategy.
The Johnson & Johnson-Spravato (esketamine) CIII Nasal Spray is indicated, in conjunction with an oral antidepressant (AD), for the treatment of treatment-resistant depression (TRD) in adults. The treatment of TRD takes place over two phases (induction and maintenance) in a clinical setting under the direct supervision of a trained health care provider. It got marketing authorization in both US and Europe.
Coverage for Spravato will vary by payer, individual contracts, and treatment setting. When provided under the supervision of an HCP in an authorized site of care, the drug will often be covered under the payer's medical benefit.
To keep up with current market trends, we take KOLs and SME's opinion working in Treatment-resistant depression (TRD) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Treatment-resistant depression (TRD) market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive & Market Intelligence analysis of the Treatment-resistant depression (TRD) Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies: